INFLIXIMAB

Course overview

INFLIXIMAB IS A BIOLOGIC, MONOCLONAL-ANTIBODY DRUG. THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED INFLIXIMAB FOR MODERATE TO SEVERELY ACTIVE CROHN DISEASE IN ADULTS AND CHILDREN (SIX YEARS AND ABOVE), ULCERATIVE COLITIS, ACTIVE RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, PSORIATIC ARTHRITIS, AND CHRONIC SEVERE PLAQUE PSORIASIS IN ADULT PATIENTS. THIS ACTIVITY DESCRIBES THE MODE OF ACTION OF INFLIXIMAB, INCLUDING ADVERSE EVENT PROFILES AND OTHER KEY FACTORS, E.G., DOSING, PHARMACODYNAMICS, PHARMACOKINETICS, MONITORING, AND HIGHLIGHTS THE INTERPROFESSIONAL TEAM'S ROLE IN MANAGING THESE PATIENTS.